PharmTeam

Seth Robey

Seth has always had a passion for scientific discovery, particularly biology and medicine. Seth studied biochemistry at Brandeis University. Now, as a PhD student of Molecular Pharmacology at Columbia University, Seth studies the drugs that help treat cardiac arrhythmias. He's thrilled to be a Motley Fool Contributor, and uncover new and exciting scientific discoveries that could improve our approach to medicine, and provide strong long term investments. Follow @SethRobey on twitter.

PharmTeam’s Activity

Fri Jul 25

PharmTeam recommended TMFGebinr's post on a Motley Fool Stock Advisor board. 4:29 PM

Rule Breakers Boards Post

PharmTeam replied to the Rule Breakers boards. 4:21 PM

Thu Jul 24

Stock Advisor Boards Post

PharmTeam replied to the Stock Advisor boards. 10:13 AM

Tue Jul 22

Rule Breakers Boards Post

PharmTeam replied to the Rule Breakers boards. 8:54 AM

Sat Jul 19

NL

Article

PharmTeam published an article 2:05 PM

10 Problems Electronic Health Records Can Help Solve

Electronic health records will be a central player in the future of health care and health care reform, and they may be even more useful than you might think.

Thu Jul 17

Caps Pick

PharmTeam made a pick in CAPS. 9:41 AM

Aegerion Pharmaceuticals, Inc. (AEGR) will Underperform the S&P 500

Thu Jul 10

Rule Breakers Boards Post

PharmTeam replied to the Rule Breakers boards. 11:10 PM

NL

Article

PharmTeam published an article 9:30 AM

Are Cancer Vaccines Worth an Investment?

Immuno-oncology has been the darling of biotech investors, but growth in one segment of the industry might not look as strong as you think.

Tue Jul 8

Stock Advisor Boards Post

PharmTeam posted to the Stock Advisor boards. 12:18 PM

Stock Advisor Boards Post

PharmTeam replied to the Stock Advisor boards. 10:48 AM

Sun Jul 6

Rule Breakers Boards Post

PharmTeam replied to the Rule Breakers boards. 8:40 PM

Thu Jul 3

Caps Pick

PharmTeam made a pick in CAPS. 12:40 PM

SolarCity (SCTY) will Outperform the S&P 500

Mon Jun 30

NL

Article

PharmTeam published an article 1:00 PM

Why Are Companion Diagnostics So Important?

Patients, doctors, and investors have been excited about new frontiers in oncology, but can these drugs be useful without companion diagnostics?

Sun Jun 22

PharmTeam recommended buyn2hold's post on a Motley Fool Rule Breakers board. 10:16 PM

Sun Jun 15

NL

Article

PharmTeam published an article 2:00 PM

Is Apple Disrupting Health Care's Disruptors?

With its new operating system and health app interface, Apple will enable doctors to play more of a role in patient-focused care. How will that change the landscape of health care IT providers?

Thu Jun 12

PharmTeam recommended millsbob's post on a Motley Fool Stock Advisor board. 10:07 AM

PharmTeam recommended FrankDip's post on a Motley Fool Stock Advisor board. 10:07 AM

Stock Advisor Boards Post

PharmTeam replied to the Stock Advisor boards. 9:50 AM

Mon Jun 2

NL

Article

PharmTeam published an article 2:30 PM

ASCO 2014: Doubling Down on Next-Gen Cancer Drugs

What's better than a cancer treatment that binds specifically to its target? A therapy that specifically binds to two targets, of course.

NL

Article

PharmTeam published an article 9:35 AM

ASCO Showdown: AstraZeneca vs. Clovis Oncology

The annual meeting brings together some of the world's most exciting emerging cancer treatments, and after only a day AztraZenica and Clovis are making waves as the compete in the lung cancer market.

Show More Activity ...

CAPS Stats & Trivia

CAPS Player Rating 61.00
Player Rank 29248 out of 74986
Score 264.10
Score Change Today +12.67
Accuracy 50.00%
Active Picks 53
Total Picks 72
Best Pick ILMN (+113.18)
Worst Pick CYTK (-76.67)
Average Score per Pick 3.67
Charms Earned 4
Highest Rated Favorite No Favorites Selected
Go to PharmTeam’s CAPS page

Boards Stats & Trivia

Board Posts 23
Recs Received 19
People who have rec'd these posts 16
Recs to Posts Ratio (last 30 days) N/A
Threads Started 8
Threads Started Percentage 34.78 %
Most Frequent Board Motley Fool Rule Breakers
Very First Post A SAS: Amazon.com post. (12/1/2013)
Percentage of Posts Rec'd 39.13 %
Show PharmTeam’s 10 Latest Posts